Esperion Therapeutis.Inc. buy StockNews.com
Summary
This prediction ended on 06.10.25 with a price of €2.80. With a performance of 41.81% the BUY prediction by StockNews_com was a big success. StockNews_com has a follow-up prediction for Esperion Therapeutis.Inc. where he still thinks Esperion Therapeutis.Inc. is a Buy. StockNews_com has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | -14.043% | -14.043% | 20.068% |
iShares Core DAX® | 0.641% | 3.579% | 27.134% |
iShares Nasdaq 100 | 2.167% | 6.631% | 17.570% |
iShares Nikkei 225® | 4.902% | 9.562% | 13.355% |
iShares S&P 500 | 1.672% | 4.814% | 11.218% |
Comments by StockNews_com for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Current prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
26.10.24
26.10.25
09.10.25
Stopped prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
17.08.25
17.08.26
09.10.25